SHISEIDO-CO.,-LTD.
Shiseido Co., Ltd. (TOKYO:4911) announces plans to open the Shiseido Cell-Processing and Expansion Center (SPEC) on May 1, 2014. The center, located in the in the Kobe Biomedical Innovation Cluster in Kobe, Japan, will centralize research and development on hair regenerative medicine with an aim toward commercialization.
Regenerative medicine in Japan is an emerging industry which the government aims to foster through new legislation and revisions to existing law as part of economic reform strategies, in order to advance in this field. Shiseido has a long history of conducting comprehensive research and working towards commercialization of the regenerative medicine for hair.
Shiseido’s hair regenerative medicine technology
With the goal of clinical application of regenerative medicine to treat alopecia and thinning hair, Shiseido concluded a technical collaboration agreement in July 2013 with a Canadian bio-venture company RepliCel Life Sciences Inc. (hereinafter referred to as “RepliCel”) acquiring an exclusive geographic license to use RepliCel Hair-01 (RCH-01) hair regeneration technology in Asia, including Japan.
RCH-01 has been developed over 10 years of scientific research, and safe
application in humans has been validated by RepliCel’s phase 1 clinical
trial. RepliCel has patents issued for hair follicle mesenchymal stem
cells and their usage in Japan, the United States, Australia and the EU.
RCH-01 is an “autologous cell transplantation technology,” in which
specific cells(1)
isolated from the hair follicles(2)
taken
from the scalp of a patient are cultured and implanted (injected) into
the balding scalp area, potentially stimulating residing hair follicles
and promoting new growth in the balding scalp area.
(1) Dermal
Sheath Cup cells, which are believed to play an important role in
promoting hair growth
(2) A hair follicle is a skin organ composed
of various cell types that support hair growth and structure.
Kobe Biomedical Innovation Cluster
The Kobe Biomedical Innovation Cluster is one of the core bases of the Kansai Innovation International Strategic Comprehensive Special Zone designated by the Japanese government to promote industrial development in advanced medicine and to provide a competitive advantage in the international market. It is the largest national cluster zone specialized in life sciences, with the focus on promoting translation of leading scientific research and advanced knowledge in regenerative medicine into clinical use.
-
Kobe Biomedical Innovation Cluster
Located in Kobe Port Island, it has been endorsed by the city of Kobe to promote its commercialization through integration of industry, academia, and government. There are over 270 biomedical companies, academic, medical, and government organizations situated in this area and working in collaboration towards clinical application of regenerative medicine, and the development of new pharmaceutical products and medical equipment.
-
Business Support Center for Biomedical Research
Activities
SPEC will be located in the Business Support Center for Biomedical Research Activities, a core facility consisting of research and CPC sections. It has been built to provide support and space for research and commercialization of regenerative medicine.
Address: 1-5-5 Minatojimaminamimachi, Chuo-ku, Kobe-shi, Hyogo 650-0047, Japan
For more information, please visit: http://www.shiseido.co.jp/releimg/2289-e.pdf
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140421005994/en/
Contact:
Shiseido Co,. Ltd.
Tatsuyoshi Endo, +81-3-6218-5200
PR
Department
tatsuyoshi.endo@to.shiseido.co.jp
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Kioxia Receives IEEE Corporate Innovation Award9.5.2025 09:00:00 CEST | Press release
Kioxia Corporation, a world leader in memory solutions, today announced that it has received the IEEE Corporate Innovation Award from the Institute of Electrical & Electronics Engineers (IEEE), the world’s largest technical professional organization dedicated to advancing technology for the benefit of humanity. This award recognizes Kioxia's outstanding contribution in the field of electrical and electronics engineering through its BiCS FLASH™ technology, a low-cost, high-capacity 3D flash memory innovation. The award ceremony was held on April 24 in Tokyo. The IEEE Corporate Innovation Award is a globally-recognized honor bestowed upon organizations that have developed innovative technologies, products or services that have made a substantial contribution to the advancement of electrical and electronics engineering. Since its inception in 1985, the award has been presented to leading electronics manufacturers and IT companies worldwide, and Kioxia is proud to be the seventh Japanese c
Suzano Reports Record First-Quarter Revenue9.5.2025 02:12:00 CEST | Press release
Suzano, the world’s largest pulp producer, announces its first quarter results for 2025 (1Q25) with record net revenue of R$11.6 billion, up 22% on the same quarter last year (1Q24). The result was driven by the exchange rates, increased pulp sales volumes from the new Ribas do Rio Pardo mill, higher paper volume and prices and the positive contribution from our paperboard mills recently acquired in the U.S. The record revenues occurred despite a series of planned downtimes in the quarter, including production lines of the Três Lagoas Unit, Mucuri Unit, and Aracruz Unit, and the Ribas do Rio Pardo Unit’s first scheduled maintenance downtime. Sales exceeded 3 million tonnes in the quarter, a rise of 12% compared to 1Q24, comprising 2.7 million tonnes of pulp and 390 thousand tonnes of paper, up 10% and 25%, respectively, on the same quarter last year. Adjusted EBITDA totaled R$4.9 billion, a 7% increase over 1Q24. Operating cash generation totaled R$2.6 billion, rising 5% on 1Q24. Net p
Andersen Consulting udvider platformen i Asien og Stillehavsområdet med tilføjelsen af Sertis8.5.2025 23:13:00 CEST | Pressemeddelelse
Andersen Consulting udvider sin dækning i Thailand og Indonesien med sin nyeste medlemsvirksomhed, Sertis, et førende konsulentfirma, der leverer datadrevne AI-løsninger til virksomheder i og uden for Sydøstasien. Dette strategiske skridt styrker Andersen Consultings tilstedeværelse i regionen og styrker organisationens kompetencer inden for AI-området. Sertis blev grundlagt i 2014 af Tee Vachiramon og har specialiseret sig i konsulenttjenester inden for AI og teknologitransformation, herunder udvikling af AI-strategi, tilpassede AI-løsninger, dataanalyse og digital omstilling. Firmaet arbejder med kunder i forskellige sektorer, herunder finans, detailhandel, energi, sundhedspleje og produktion, og sætter dem i stand til at optimere driften, træffe bedre beslutninger og forbedre kundeoplevelsen. "At blive medlem af Andersen Consulting er en milepæl for vores firma, da det giver os mulighed for at trække på en enestående platform med brancheførende løsninger til vores kunder," siger Tee
GC Aesthetics® Strengthens Board of Directors with Strategic Appointments8.5.2025 17:10:00 CEST | Press release
GC Aesthetics® (GCA), a privately-held medical technology company providing aesthetic and reconstruction solutions for global healthcare markets is pleased to announce the appointment of Mr. Luigi Ferrari as Chairman of the Board (non-executive) and Mr. Patrick Lee as Board Director, reinforcing the company’s strategic direction and long-term growth plans. These appointments follow the renewed phase of partnership initiated in early 2024 with Hayfin Capital Management, a longstanding investor in GCA. This collaboration has brought fresh momentum to the company’s commitment to innovation, safety, and global expansion in aesthetic and reconstructive breast surgery. Luigi Ferrari, a seasoned executive and investor with a proven track record in the healthcare sector, brings deep leadership experience, commercial growth expertise and industry insight. From 2012 to 2022 he was CEO of Lima Corporate, a global medical device company in the joint replacement market, acquired then by Enovis Corp
PPG to invest $380 million to buildnew U.S. manufacturing facility in Shelby, N.C. for aerospace coatings and sealants8.5.2025 16:30:00 CEST | Press release
PPG (NYSE: PPG) today announced that it will invest $380 million to build a new aerospace coatings and sealants manufacturing facility in Shelby, N.C. Construction on the 62-acre site, which will initially include manufacturing and warehousing units, is set to commence in October 2025 and is expected to be completed in the first half of 2027. The 198,000-square-foot facility will enable the company to continue meeting the growing demands of the aerospace industry. It will employ more than 110 people and produce the full line of PPG’s aerospace coatings and sealants. The additional capacity of this new plant, combined with nearby transport links that improve supply chain and shipping logistics, will help improve service levels for customers. “PPG’s investment in this new manufacturing facility demonstrates the significant demand growth for our world-class technologies and our continued commitment to serving our aerospace customers,” said Tim Knavish, PPG chairman and chief executive off
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum